Aragen acquires Intox
Strengthens discovery-to-development integrated platform with the addition of GLP-certified safety-assessment capabilities
Aragen Life Sciences has signed a definitive agreement to acquire Pune-based Intox. This acquisition will expand Aragen’s end-to-end integrated discovery and development platform for the pharmaceuticals, biotechnology, animal health and agrochemicals industries. It will enable Aragen to conduct safety assessment studies from a Good Laboratory Practice (GLP)-certified facility for submission to regulatory agencies such as the US Food and Drug Administration (FDA), the US Environment Protection Agency (USEPA), the European Medicines Agency (EMA), and others, globally, the companies notified via a joint statement.
The statement said that the acquisition will also expand Aragen’s geographical footprint in India. Aragen currently has research and manufacturing facilities at Hyderabad, Bengaluru and Vizag in India and a biologics facility in California, the US.
- Advertisement -